An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report

The clinical activity and favorable toxicity profile of osimertinib has led it to be approved not only for advanced non-small cell lung cancer (NSCLC) patients with T790M-positive tumors when first, or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Zhou, Fei, Xie, Huikang, Wu, Yan, Zhao, Jing, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225156/
https://www.ncbi.nlm.nih.gov/pubmed/32420075
http://dx.doi.org/10.21037/tlcr.2020.02.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225156/
https://www.ncbi.nlm.nih.gov/pubmed/32420075
http://dx.doi.org/10.21037/tlcr.2020.02.09

Ejemplares similares